TG Therapeutics Inc (TGTX)

Form 8-K - Current report

TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)

Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under...

TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael...

TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology

Treatment with BRIUMVI reduced annualized relapse rate by 56.7% vs. teriflunomide in treatment-naïve patients...

TG Therapeutics to Participate in the Jefferies Global Healthcare Conference

NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael...

Form 8-K - Current report

TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial

Phase 3 trial met its primary endpoint, demonstrating bioequivalent drug exposure between the currently...

TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance

First quarter 2026 total global revenue of approximately $205 million, including BRIUMVI U.S. net revenue of...

Form DEF 14A - Other definitive proxy statements

TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update

NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting

NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the...